Population screening for isoniazid acetylator phenotype

被引:26
作者
Seifart, HI
Parkin, DP
Botha, FJH
Donald, PR
Van der Walt, BJ
机构
[1] Univ Stellenbosch, Sch Med, Dept Pharmacol, ZA-7505 Tygerberg, South Africa
[2] Univ Stellenbosch, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa
关键词
isoniazid; arylamine N-acetyltransferase; acetylation; phenotype; polymorphism; trimodality; efficacy; bioavailability; drug monitoring;
D O I
10.1002/pds.570
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose - To establish a useful method for acetylator phenotypification and therapeutic drug monitoring of patients receiving isoniazid. Methods - Sixty patients with uncomplicated pulmonary tuberculosis were given a 5-mg/kg oral dose of isoniazid each. Plasma concentrations of isoniazid and its metabolite, acetyl-isoniazid, were determined by HPLC analyses at various postdose times. From the isoniazid concentration and the concentration ratio of acetyl-isoniazid and isoniazid (metabolic ratio), phenotypification methods were assessed. Results - The metabolic ratios at 3 h post-dose revealed a trimodal distribution; a fast, intermediate and slow acetylator phenotype group. The 2-h and 6-h data showed different bimodal combinations of these phenotype groups. The metabolic ratio phenotypification method could be simplified by using the HPLC data directly without converting it to absolute concentrations. Conclusions - A single-sample test based upon the plasma isoniazid concentration, combined with the metabolic ratio of acetyl-isoniazid and isoniazid, appears to be a reliable parameter for phenotype discrimination and for bioavailability testing. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 25 条
[1]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[2]  
Cohen J., 1998, Statistical Power Analysis for the Behavioral Sciences, V2nd
[3]  
ELLARD GA, 1993, TUBERCLE, V54, P201
[4]   GPOWER: A general power analysis program [J].
Erdfelder, E ;
Faul, F ;
Buchner, A .
BEHAVIOR RESEARCH METHODS INSTRUMENTS & COMPUTERS, 1996, 28 (01) :1-11
[5]  
GIBALDI M, 1982, PHARMACOKINETICS, P344
[6]  
Gross M, 1999, CANCER EPIDEM BIOMAR, V8, P683
[7]  
Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29
[8]   A SIMPLE METHOD FOR DETERMINING ACETYLATOR PHENOTYPE USING ISONIAZID [J].
HUTCHINGS, A ;
ROUTLEDGE, PA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (03) :343-345
[9]   POLYMORPHIC DRUG OXIDATION - PHARMACOKINETIC BASIS AND COMPARISON OF EXPERIMENTAL INDEXES [J].
JACKSON, PR ;
TUCKER, GT ;
LENNARD, MS ;
WOODS, HF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (05) :541-550
[10]   DETERMINATION OF ISONIAZID AND ACETYLISONIAZID IN PLASMA OR SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
LACROIX, C ;
LAINE, G ;
GOULLE, JP ;
NOUVEAU, J .
JOURNAL OF CHROMATOGRAPHY, 1984, 307 (01) :137-144